Gatien Moriceau

Title(s)Associate Adjunct Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024; 15:1487952. Chow F, Lamoureux F, Moriceau G. PMID: 39391312; PMCID: PMC11464455.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    2. Expression of Concern: Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2024 07 01; 14(7):1356. Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS. PMID: 38946327.
      View in: PubMed   Mentions:    Fields:    
    3. Expression of Concern: Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2024 07 01; 14(7):1357. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. PMID: 38946326.
      View in: PubMed   Mentions:    Fields:    
    4. Multi-organ landscape of therapy-resistant melanoma. Nat Med. 2023 05; 29(5):1123-1134. Liu S, Dharanipragada P, Lomeli SH, Wang Y, Zhang X, Yang Z, Lim RJ, Dumitras C, Scumpia PO, Dubinett SM, Moriceau G, Johnson DB, Moschos SJ, Lo RS. PMID: 37106167; PMCID: PMC10202813.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    5. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. Cancer Discov. 2023 04 03; 13(4):880-909. Dharanipragada P, Zhang X, Liu S, Lomeli SH, Hong A, Wang Y, Yang Z, Lo KZ, Vega-Crespo A, Ribas A, Moschos SJ, Moriceau G, Lo RS. PMID: 36700848; PMCID: PMC10068459.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    6. Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH. Nat Genet. 2022 11; 54(11):1746-1754. Hung KL, Luebeck J, Dehkordi SR, Colón CI, Li R, Wong IT, Coruh C, Dharanipragada P, Lomeli SH, Weiser NE, Moriceau G, Zhang X, Bailey C, Houlahan KE, Yang W, González RC, Swanton C, Curtis C, Jamal-Hanjani M, Henssen AG, Law JA, Greenleaf WJ, Lo RS, Mischel PS, Bafna V, Chang HY. PMID: 36253572; PMCID: PMC9649439.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    7. Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer Discov. 2022 08 05; 12(8):1942-1959. Yang Z, Wang Y, Liu S, Deng W, Lomeli SH, Moriceau G, Wohlschlegel J, Piva M, Lo RS. PMID: 35638972; PMCID: PMC9357203.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    8. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. Cancer Discov. 2022 04 01; 12(4):1046-1069. Song K, Minami JK, Huang A, Dehkordi SR, Lomeli SH, Luebeck J, Goodman MH, Moriceau G, Krijgsman O, Dharanipragada P, Ridgley T, Crosson WP, Salazar J, Pazol E, Karin G, Jayaraman R, Balanis NG, Alhani S, Sheu K, Ten Hoeve J, Palermo A, Motika SE, Senaratne TN, Paraiso KH, Hergenrother PJ, Rao PN, Multani AS, Peeper DS, Bafna V, Lo RS, Graeber TG. PMID: 34930786; PMCID: PMC9192483.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    9. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021 10 11; 39(10):1375-1387.e6. Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. PMID: 34416167; PMCID: PMC9126729.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimals
    10. SPRED1 deletion confers resistance to MAPK inhibition in melanoma. J Exp Med. 2021 03 01; 218(3). Ablain J, Liu S, Moriceau G, Lo RS, Zon LI. PMID: 33306107; PMCID: PMC7927430.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    11. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2021 03; 11(3):714-735. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. PMID: 33318037; PMCID: PMC7933113.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    12. High-Speed Live-Cell Interferometry: A New Method for Quantifying Tumor Drug Resistance and Heterogeneity. Anal Chem. 2018 03 06; 90(5):3299-3306. Huang D, Leslie KA, Guest D, Yeshcheulova O, Roy IJ, Piva M, Moriceau G, Zangle TA, Lo RS, Teitell MA, Reed J. PMID: 29381859.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    13. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov. 2018 01; 8(1):74-93. Hong A, Moriceau G, Sun L, Lomeli S, Piva M, Damoiseaux R, Holmen SL, Sharpless NE, Hugo W, Lo RS. PMID: 28923912; PMCID: PMC6456057.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimals
    14. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017 11; 7(11):1248-1265. Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. PMID: 28864476; PMCID: PMC6668729.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    15. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016; 2:16028. Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG. PMID: 27648299; PMCID: PMC5012007.
      View in: PubMed   Mentions: 31  
    16. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10; 162(6):1271-85. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. PMID: 26359985; PMCID: PMC4821508.
      View in: PubMed   Mentions: 327     Fields:    Translation:HumansCells
    17. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015 Jul 03; 13:210. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. PMID: 26139106; PMCID: PMC4490757.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    18. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. PMID: 25600339; PMCID: PMC4326539.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansCells
    19. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One. 2014; 9(3):e90795. Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Redini F, Heymann D. PMID: 24599309; PMCID: PMC3944320.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    20. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. PMID: 24265155; PMCID: PMC3936420.
      View in: PubMed   Mentions: 504     Fields:    Translation:HumansCells
    21. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. PMID: 24265152; PMCID: PMC3893054.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    22. Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro. J Biomed Mater Res A. 2013 Apr; 101(4):991-7. Lionetto S, Little A, Moriceau G, Heymann D, Decurtins M, Plecko M, Filgueira L, Cadosch D. PMID: 22965942.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    23. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012 Aug; 18(8):1239-47. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC. PMID: 22820643; PMCID: PMC3744207.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansAnimalsCells
    24. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. PMID: 22588879; PMCID: PMC3594852.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    25. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. PMID: 22395615; PMCID: PMC3530385.
      View in: PubMed   Mentions: 320     Fields:    Translation:HumansCells
    26. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. PMID: 22113612; PMCID: PMC3266695.
      View in: PubMed   Mentions: 750     Fields:    Translation:HumansAnimalsCells
    27. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 2012 Feb 01; 118(3):750-60. Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. PMID: 21751201.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    28. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010 Dec 15; 70(24):10329-39. Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, Mönkkönen J, Rédini F, Heymann D. PMID: 20971812; PMCID: PMC3097388.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    29. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des. 2010; 16(27):2981-7. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D. PMID: 20722622.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    30. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta. 2010 Jan; 1805(1):17-24. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. PMID: 19733222.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    31. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med. 2008 Jun; 12(3):928-41. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Rédini F, Rogers M, Heymann D. PMID: 18494934; PMCID: PMC4401135.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    32. mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem. 2007; 14(13):1381-7. Ory B, Moriceau G, Redini F, Heymann D. PMID: 17584050.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    Gatien's Networks
    Concepts (170)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (22)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California